Patent Search Skill

Comprehensive patent analysis for drug discovery and IP intelligence.

Quick Start

/patent EGFR inhibitor
/fto "quinazoline EGFR kinase"
/patent-map KRAS G12C
Analyze patent landscape for osimertinib

What's Included

Section	Description	Data Source
Patent Search	Find relevant patents	USPTO, EPO, WIPO
Patent Details	Claims, assignees, priority	Patent databases
FTO Analysis	Freedom to operate assessment	Claims analysis
Landscape Map	Patent clustering and gaps	Aggregated
Expiration	Patent expiry dates	Patent databases
Family Analysis	Patent family members	Global Dossier

Output Structure

# Patent Analysis: EGFR Inhibitors

## Executive Summary
**Total Patents**: 3,247 EGFR inhibitor patents found
**Key Patent Families**: 89 unique families
**FTO Risk**: High - crowded landscape with broad claims

## Patent Landscape
| Time Period | Patents | Growth |
|-------------|---------|--------|
| 1990-1999 | 234 | Baseline |
| 2000-2009 | 892 | +281% |
| 2010-2019 | 1,456 | +63% |
| 2020-2024 | 665 | Declining |

## Key Patent Families

### US5747498 (Erlotinib)
| Field | Value |
|-------|-------|
| Assignee | OSI Pharmaceuticals |
| Priority Date | 1994-04-15 |
| Grant Date | 1998-05-05 |
| Expiry | 2018 (expired) |
| Claims | 47 claims |
| Scope | Quinazoline EGFR inhibitors |

### US8017621 (Gefitinib)
| Field | Value |
|-------|-------|
| Assignee | AstraZeneca |
| Priority Date | 1992-03-06 |
| Expiry | 2014 (expired) |
| Scope | Broad EGFR TKI claims |

## FTO Analysis

### High-Risk Patents
| Patent | Risk | Reason |
|--------|------|--------|
| US8772358 | ⚠️ High | 3rd-gen TKI, C797S active |
| US10363010 | ⚠️ High | Broad mutant-selective claims |
| US10588034 | ⚠️ High | Combination therapy claims |

### White Space
| Area | Opportunity | Rationale |
|------|-------------|----------|
| 4th-gen TKI | Low IP pressure | C797S+S1278 niche |
| Allosteric sites | Emerging | Fewer existing claims |
| Bispecific formats | Moderate | Combination IP possible |

## Patent Family Analysis
**Example: Osimertinib (AZD9291)**

| Jurisdiction | Patent | Status | Expiry |
|-------------|--------|--------|--------|
| US | US8772358 | Expired | 2033 |
| EP | EP2378967 | Granted | 2033 |
| JP | JP5958971 | Granted | 2033 |
| CN | CN102822420 | Granted | 2033 |

## Claim Analysis
**US8772358 Claim 1 (Representative):**

A compound of formula (I) or a pharmaceutically acceptable salt thereof, for use in the treatment of a proliferative disease mediated by EGFR having the T790M mutation...

**Breadth:** Broad - covers mutant-selective EGFR inhibitors
**Enforceability:** High - well-defined structure
**Workaround:** Difficult - covers core scaffold

## Competitive IP Map
| Company | Patent Families | Core Focus |
|----------|-----------------|-------------|
| AstraZeneca | 12 | 3rd-gen TKI, combinations |
| Johnson & Johnson | 8 | Bispecific antibodies |
| Daiichi Sankyo | 6 | ADC conjugates |
| Blueprint Medicines | 4 | 4th-gen TKI |
| Yuhan/Roche | 3 | Lazertinib combinations |

Examples

Patent Search

/patent EGFR quinazoline
/patent-search "KRAS G12C inhibitor"
Find all patents for sotorasib

FTO Analysis

/fto "EGFR TKI scaffold"
/fto-analysis compound.smi
Can I make this compound without infringement?

Landscape Mapping

/patent-map KRAS inhibitors
Map patent landscape for 4th-gen EGFR
Analyze IP gaps in PROTAC EGFR degraders

Patent Family

/patent US8772358 --family
/patent WO2010130291 --global
Show all related patents for osimertinib

Running Scripts

# Search patents by keyword
python scripts/patent_search.py "EGFR inhibitor" --output patents.json

# FTO analysis
python scripts/patent_search.py --fto "quinazoline scaffold" --claims

# Patent family lookup
python scripts/patent_search.py --family US8772358

# Landscape mapping
python scripts/patent_search.py --landscape "KRAS G12C" --cluster

# Expiration analysis
python scripts/patent_search.py --expiry "EGFR TKI" --sort-by-date

Requirements

pip install requests pandas lxml

Additional Resources

• USPTO API Reference
• EPO Register
• FTO Methodology

Best Practices

1. Start broad: Cast wide net, then filter
2. Check families: Patents span multiple jurisdictions
3. Read claims: Scope determined by claims, not abstract
4. Check expiry: Many drug patents expired
5. Consider licenses: Blocked ≠ impossible (licensing possible)

Common Pitfalls

Pitfall	Solution
Narrow search	Use multiple terms/synonyms
Ignoring families	Check global coverage
Misreading claims	Claims define scope, not title
Overlooked continuations	Check continuation-in-part (CIP)
Publication vs. grant	Check granted patent status